Pegasys

Type: Keyphrase

Name: Pegasys

First Reported Mar 11 2010 - Updated Mar 11 2010 - 1 Documents

Three TMPGEnc Programs Now Offer Windows Media Center WTV Input Support

Los Angeles - Import Windows Media Center .wtv files, Remove Unwanted Commercials, Convert Video to other Formats such as for iPod or PSP, Create DVD, DivX or Blu-ray MenusGardena, Calif. - March 10, 2010 - Pegasys, Inc. (http://tmpgenc.pegasys-inc.com) ... [Published Mar 11 2010 by dBusinessNews.com]

Entities: Pegasys, Encryption, Blu-Ray

First Reported Mar 03 2010 - Updated Mar 03 2010 - 2 Documents

Pharmasset to Present at Cowen and Company 30th Annual Healthcare

Pharmasset, Inc. announces that management will present at the Cowen and Company 30th Annual Healthcare Conference being held from March 8 to 11, 2010 at the Boston Copley Marriot Place, Boston, MA.Schaefer Price, Pharmasset's President and Chief Executive ... [Published Mar 03 2010 by PR Newswire via MSN Money]

Entities: Pharmasset Inc, Pegasys, Nucleoside, ribavirin

First Reported Feb 17 2010 - Updated Feb 18 2010 - 1 Documents

Pharmasset Announces Complete Enrollment of RG7128 Phase 2b

Roche Initiating Additional Clinical Studies with RG7128- INFORM Studies DelayedPR wirePRINCETON, N.J., Feb. 17PRINCETON, N.J., Feb. 17 /PRwire-FirstCall/ -- Pharmasset, Inc. announced today the complete enrollment by Roche of the 12 week RG7128 Phase ... [Published Feb 17 2010 by PR Newswire via MSN Money]

Entities: Pharmasset Inc, ribavirin, Interferon, Genotype, Pegasys

First Reported Feb 12 2010 - Updated Feb 12 2010 - 1 Documents

Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?

is standard therapy for chronic hepatitis C, but there has not been consensus about the relative benefits of Pegasys (Roche/Genentech) and PegInton (Schering-Plough). Past research has produced conflicting findings, and data have not always been strictly ... [Published Feb 12 2010 by HIV and Hepatitis.com]

Entities: Pegasys, Interferon, Genotype, Hepatitis C, ribavirin

First Reported Oct 16 2009 - Updated Oct 16 2009 - 1 Documents

Roche Holding Ltd

Roche - Full-year outlook raised

Roche has reported further accelerated sales growth in third quarter, and now expects at least high single-digit full-year sales growth for Pharmaceuticals Division; full-year 2009 sales in both divisions expected to grow well ahead of market.Pharma sales ... [Published Oct 16 2009 by PharmiWeb]

Entities: Roche Holding Ltd, European Union, Tamiflu

Quotes

"The HGS financial position was significantly strengthened during 2009," said Tim Barabe, Senior Vice President and Chief Financial Officer. "With the proceeds from two successful public offerings of HGSI common stock, our cash position is more than sufficient to take us through the filing of marketing applications and the launch of our late-stage products, while also continuing to enable investment in our earlier-stage pipeline. Excluding $813 million in new funding, we realized net cash flow of nearly $30 million in 2009."

Human Genome Sciences Reports 4Q and Full-Year 2009 Financial Res... [Zibb - Mar 04 2010]

More Content

sort by: Date \| Relevance
Potential Buyers Are Circling Around This Mobil... [Dotmed - Mar 11 2010]
Three TMPGEnc Programs Now Offer Windows Media ... [dBusinessNews.com - Mar 11 2010]
Flamel Technologies S.A. Q4 2009 Earnings Call ... [Seeking Alpha - Mar 09 2010]
Reportlinker Adds Global Anti-Infectives Industry [Yahoo! Canada - Mar 08 2010]
Expand Your MRI Imaging Capabilities Fast -- Wi... [Dotmed - Mar 04 2010]
Human Genome Sciences Reports 4Q and Full-Year ... [Zibb - Mar 04 2010]
Human Genome Sciences Reports 4Q and Full-Year ... [TradingMarkets - Mar 04 2010]
Pharmasset to Present at Cowen and Company 30th... [PR Newswire via MSN Money - Mar 03 2010]
Pharmasset to Present at Cowen and Company 30th... [FinanzNachrichten.de - Mar 03 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Forbes.com - Mar 02 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Street Insider - Mar 02 2010]
Human Genome Sciences Announces Fourth-Quarter ... [Stockwatch - Mar 02 2010]
Abacavir (Ziagen) Does Not Compromise Effective... [HIV and Hepatitis.com - Mar 02 2010]
/C O R R E C T I O N -- Anadys Pharmaceuticals,... [RBC Dain Rauscher - Feb 25 2010]
/C O R R E C T I O N -- Anadys Pharmaceuticals,... [Zibb - Feb 25 2010]
Will You Get This Top-of-the-Line CT for Your R... [Dotmed - Feb 24 2010]
ANA598 Demonstrates 73% cEVR in Combination Wit... [PR Newswire via MSN Money - Feb 24 2010]
Pharmasset Announces Complete Enrollment of RG7... [PR Newswire via MSN Money - Feb 17 2010]
Global Communications Leader Porter Novelli Wel... [PR Newswire - Feb 16 2010]
Is One Type of Pegylated Interferon More Effect... [HIV and Hepatitis.com - Feb 12 2010]
Biolex Announces Locteron(R) Phase 2b Interim R... [PR inside - Feb 10 2010]
100...99...98...97.... OK, You Get It: There Ar... [Dotmed - Feb 04 2010]
Anadys Updates On ANA598 Phase II Study In Hepa... [Pharmaceutical Business Review - Jan 23 2010]
Anadys Pharmaceuticals Provides Progress Update... [Stockwatch - Jan 22 2010]
Stakeholder Insight: Hepatitis B & C In Asi... [OfficialSpin - Jan 14 2010]
Reportlinker Adds Hepatitis C Virus and Therape... [PR Newswire - Dec 02 2009]
Human Genome Sciences submits Zalbin BLA to US ... [PharmaBiz - Nov 27 2009]
ZymoGenetics initiates phase 2 trial of PEG-int... [PharmaBiz - Oct 29 2009]
Roche - Full-year outlook raised [PharmiWeb - Oct 16 2009]
Raju suffering from chronic Hepatitis C [The Hindu - Sep 08 2009]

Advanced Search Options